vs
Alight, Inc.（ALIT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Alight, Inc.的1.2倍（$772.1M vs $653.0M），Revvity净利率更高（12.7% vs -142.7%，领先155.5%），Revvity同比增速更快（5.9% vs -4.0%），Revvity自由现金流更多（$161.8M vs $99.0M），过去两年Revvity的营收复合增速更高（9.0% vs 8.1%）
Alight公司是一家美国信息技术与咨询企业，专注于人力资源相关业务，主打基于云的系统服务、业务外包与咨询服务，为大型企业提供人力资本管理平台与外包方案，业务范围涵盖健康福利管理、财务管理以及退休规划等领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ALIT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$653.0M
营收增速更快
RVTY
高出9.8%
-4.0%
净利率更高
RVTY
高出155.5%
-142.7%
自由现金流更多
RVTY
多$62.8M
$99.0M
两年增速更快
RVTY
近两年复合增速
8.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $653.0M | $772.1M |
| 净利润 | $-932.0M | $98.4M |
| 毛利率 | 36.8% | — |
| 营业利润率 | -114.9% | 14.5% |
| 净利率 | -142.7% | 12.7% |
| 营收同比 | -4.0% | 5.9% |
| 净利润同比 | -11750.0% | 3.9% |
| 每股收益（稀释后） | $-1.77 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALITRVTY
| Q4 25 | $653.0M | $772.1M | ||
| Q3 25 | $533.0M | $698.9M | ||
| Q2 25 | $528.0M | $720.3M | ||
| Q1 25 | $548.0M | $664.8M | ||
| Q4 24 | $680.0M | $729.4M | ||
| Q3 24 | $555.0M | $684.0M | ||
| Q2 24 | $538.0M | $691.7M | ||
| Q1 24 | $559.0M | $649.9M |
净利润ALITRVTY
| Q4 25 | $-932.0M | $98.4M | ||
| Q3 25 | $-1.1B | $46.7M | ||
| Q2 25 | $-1.1B | $53.9M | ||
| Q1 25 | $-25.0M | $42.2M | ||
| Q4 24 | $8.0M | $94.6M | ||
| Q3 24 | $-74.0M | $94.4M | ||
| Q2 24 | $23.0M | $55.4M | ||
| Q1 24 | $-114.0M | $26.0M |
毛利率ALITRVTY
| Q4 25 | 36.8% | — | ||
| Q3 25 | 33.4% | 53.6% | ||
| Q2 25 | 33.3% | 54.5% | ||
| Q1 25 | 31.2% | 56.5% | ||
| Q4 24 | 39.9% | — | ||
| Q3 24 | 31.4% | 56.3% | ||
| Q2 24 | 31.0% | 55.7% | ||
| Q1 24 | 32.6% | 54.6% |
营业利润率ALITRVTY
| Q4 25 | -114.9% | 14.5% | ||
| Q3 25 | -248.0% | 11.7% | ||
| Q2 25 | -191.3% | 12.6% | ||
| Q1 25 | -1.5% | 10.9% | ||
| Q4 24 | 6.5% | 16.3% | ||
| Q3 24 | -7.6% | 14.3% | ||
| Q2 24 | -9.7% | 12.4% | ||
| Q1 24 | -7.2% | 6.8% |
净利率ALITRVTY
| Q4 25 | -142.7% | 12.7% | ||
| Q3 25 | -200.2% | 6.7% | ||
| Q2 25 | -203.2% | 7.5% | ||
| Q1 25 | -4.6% | 6.4% | ||
| Q4 24 | 1.2% | 13.0% | ||
| Q3 24 | -13.3% | 13.8% | ||
| Q2 24 | 4.3% | 8.0% | ||
| Q1 24 | -20.4% | 4.0% |
每股收益（稀释后）ALITRVTY
| Q4 25 | $-1.77 | $0.86 | ||
| Q3 25 | $-2.02 | $0.40 | ||
| Q2 25 | $-2.03 | $0.46 | ||
| Q1 25 | $-0.05 | $0.35 | ||
| Q4 24 | $0.02 | $0.77 | ||
| Q3 24 | $-0.14 | $0.77 | ||
| Q2 24 | $0.04 | $0.45 | ||
| Q1 24 | $-0.21 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $273.0M | $919.9M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $1.0B | $7.3B |
| 总资产 | $4.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.92× | — |
8季度趋势，按日历期对齐
现金及短期投资ALITRVTY
| Q4 25 | $273.0M | $919.9M | ||
| Q3 25 | $205.0M | $931.4M | ||
| Q2 25 | $227.0M | $991.8M | ||
| Q1 25 | $223.0M | $1.1B | ||
| Q4 24 | $343.0M | $1.2B | ||
| Q3 24 | $300.0M | $1.2B | ||
| Q2 24 | $183.0M | $2.0B | ||
| Q1 24 | $256.0M | $1.7B |
总债务ALITRVTY
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.8B | — |
股东权益ALITRVTY
| Q4 25 | $1.0B | $7.3B | ||
| Q3 25 | $2.0B | $7.4B | ||
| Q2 25 | $3.1B | $7.6B | ||
| Q1 25 | $4.2B | $7.6B | ||
| Q4 24 | $4.3B | $7.7B | ||
| Q3 24 | $4.3B | $7.9B | ||
| Q2 24 | $4.5B | $7.9B | ||
| Q1 24 | $4.5B | $7.8B |
总资产ALITRVTY
| Q4 25 | $4.6B | $12.2B | ||
| Q3 25 | $5.5B | $12.1B | ||
| Q2 25 | $6.8B | $12.4B | ||
| Q1 25 | $7.9B | $12.4B | ||
| Q4 24 | $8.2B | $12.4B | ||
| Q3 24 | $8.3B | $12.8B | ||
| Q2 24 | $10.5B | $13.4B | ||
| Q1 24 | $10.7B | $13.4B |
负债/权益比ALITRVTY
| Q4 25 | 1.92× | — | ||
| Q3 25 | 1.00× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.62× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $124.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $99.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 15.2% | 21.0% |
| 资本支出强度资本支出/营收 | 3.8% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $250.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ALITRVTY
| Q4 25 | $124.0M | $182.0M | ||
| Q3 25 | $77.0M | $138.5M | ||
| Q2 25 | $86.0M | $134.3M | ||
| Q1 25 | $73.0M | $128.2M | ||
| Q4 24 | $118.0M | $174.2M | ||
| Q3 24 | $-24.0M | $147.9M | ||
| Q2 24 | $58.0M | $158.6M | ||
| Q1 24 | $100.0M | $147.6M |
自由现金流ALITRVTY
| Q4 25 | $99.0M | $161.8M | ||
| Q3 25 | $49.0M | $120.0M | ||
| Q2 25 | $58.0M | $115.5M | ||
| Q1 25 | $44.0M | $112.2M | ||
| Q4 24 | $92.0M | $149.8M | ||
| Q3 24 | $-52.0M | $125.6M | ||
| Q2 24 | $22.0M | $136.6M | ||
| Q1 24 | $69.0M | $129.7M |
自由现金流率ALITRVTY
| Q4 25 | 15.2% | 21.0% | ||
| Q3 25 | 9.2% | 17.2% | ||
| Q2 25 | 11.0% | 16.0% | ||
| Q1 25 | 8.0% | 16.9% | ||
| Q4 24 | 13.5% | 20.5% | ||
| Q3 24 | -9.4% | 18.4% | ||
| Q2 24 | 4.1% | 19.7% | ||
| Q1 24 | 12.3% | 20.0% |
资本支出强度ALITRVTY
| Q4 25 | 3.8% | 2.6% | ||
| Q3 25 | 5.3% | 2.6% | ||
| Q2 25 | 5.3% | 2.6% | ||
| Q1 25 | 5.3% | 2.4% | ||
| Q4 24 | 3.8% | 3.4% | ||
| Q3 24 | 5.0% | 3.3% | ||
| Q2 24 | 6.7% | 3.2% | ||
| Q1 24 | 5.5% | 2.7% |
现金转化率ALITRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 14.75× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 2.52× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALIT
| Recurring | $607.0M | 93% |
| Projects | $46.0M | 7% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
